Literature DB >> 30777212

The diagnostic value of 4D MRI at 3T for the localization of parathyroid adenomas.

Mesut Ozturk1, Ahmet Veysel Polat2, Cetin Celenk2, Muzaffer Elmali2, Seher Kir3, Cafer Polat4.   

Abstract

PURPOSE: The aim of this study was to assess the feasibility of four-dimensional magnetic resonance imaging (4D MRI) at 3 T for the localization of parathyroid adenomas.
MATERIALS AND METHODS: Preoperative 4D MRI scans, encompassing dynamic contrast-enhanced (DCE) sequences and non-contrast enhanced (non-CE) sequences, including a T2-weighted multipoint Dixon (T2-mDixon) sequence, with in-phase, out-phase, and water-only images, were evaluated retrospectively in 41 patients with surgically proven parathyroid lesions. Two readers who were blinded to the surgical findings independently reviewed the images in two sessions (non-CE sequences alone and non-CE + DCE sequences). The MRI localization of the suspected adenoma in each session and the consensus interpretation of the MRI images, were compared with the surgical results and interobserver agreement was assessed.
RESULTS: By interpreting the non-CE sequences alone, reader 1 correctly localized 34 parathyroid lesions (sensitivity 81.0%, positive predictive value (PPV) 87.2%), and reader 2 correctly localized 34 parathyroid lesions (sensitivity 81.0%, PPV 91.9%). With the addition of DCE sequences, reader 1 correctly identified 35 parathyroid lesions (sensitivity 83.3%, PPV 87.5%), while reader 2 correctly identified 36 parathyroid lesions (sensitivity 85.7%, PPV 92.3%). Overall, MRI detected 38 parathyroid lesions (sensitivity 90.5%, PPV 95.0%). Interobserver agreement was slightly superior in non-CE + DCE sequences compared to non-CE sequences alone (ĸ = 0.796 vs. ĸ = 0.738).
CONCLUSION: 4D MRI with DCE sequencing is a reliable method for the localization of parathyroid adenomas.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  99mTc-Sestamibi; Diagnostic performance; Magnetic resonance imaging; Parathyroid adenoma; Ultrasonography

Mesh:

Year:  2019        PMID: 30777212     DOI: 10.1016/j.ejrad.2019.01.022

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  7 in total

1.  4D-Dynamic Contrast-Enhanced MRI for Preoperative Localization in Patients with Primary Hyperparathyroidism.

Authors:  J L Becker; V Patel; K J Johnson; M Guerrero; R R Klein; G F Ranvier; R P Owen; P Pawha; K Nael
Journal:  AJNR Am J Neuroradiol       Date:  2020-03-12       Impact factor: 3.825

2.  Diagnostic value of four-dimensional computed tomography and four-dimensional magnetic resonance imaging in primary hyperparathyroidism when first-line imaging was inadequate.

Authors:  N Acar; M Haciyanli; M Coskun; N K Erdogan; S C Celik; S G Haciyanli; E O Gur
Journal:  Ann R Coll Surg Engl       Date:  2020-01-10       Impact factor: 1.891

Review 3.  Pediatric hyperparathyroidism: review and imaging update.

Authors:  Hedieh Khalatbari; Safia H E Cheeney; Scott C Manning; Marguerite T Parisi
Journal:  Pediatr Radiol       Date:  2021-04-27

4.  18F-Fluorocholine PET and Multiphase CT Integrated in Dual Modality PET/4D-CT for Preoperative Evaluation of Primary Hyperparathyroidism.

Authors:  Valentin Pretet; Marianela Rotania; Mehdi Helali; Mihaela Ignat; Michel Vix; Alessio Imperiale
Journal:  J Clin Med       Date:  2020-06-26       Impact factor: 4.241

5.  Atypical presentations of parathyroid gland pathology: A pictorial review.

Authors:  Xin-Ying Kowa; Polly Richards; Mona Waterhouse; Laila Parvanta; Ashok Adams
Journal:  Eur J Radiol Open       Date:  2019-11-08

Review 6.  Preoperative Localization for Primary Hyperparathyroidism: A Clinical Review.

Authors:  Donovan Tay; Jeeban P Das; Randy Yeh
Journal:  Biomedicines       Date:  2021-04-06

7.  18F-choline PET/CT and PET/MRI in primary and recurrent hyperparathyroidism: a systematic review of the literature.

Authors:  Laura Evangelista; Ilaria Ravelli; Fabio Magnani; Maurizio Iacobone; Chiara Giraudo; Valentina Camozzi; Alessandro Spimpolo; Diego Cecchin
Journal:  Ann Nucl Med       Date:  2020-08-07       Impact factor: 2.668

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.